Neurology International最新文献

{"title":"Genetic Variability in Vitamin D Receptor and Migraine Susceptibility: A Southeastern European Case-Control Study.","authors":"Maria Papasavva,&nbsp;Michail Vikelis,&nbsp;Vasileios Siokas,&nbsp;Martha-Spyridoula Katsarou,&nbsp;Emmanouil V Dermitzakis,&nbsp;Athanasios Raptis,&nbsp;Efthimios Dardiotis,&nbsp;Nikolaos Drakoulis","doi":"10.3390/neurolint15030069","DOIUrl":"https://doi.org/10.3390/neurolint15030069","url":null,"abstract":"<p><p>Migraine is a common primary headache disorder with both environmental and genetic inputs. Cumulative evidence indicates an association between vitamin D and headache. Unravelling the precise role of vitamin D and its receptor in the pathophysiology of migraine can eventually contribute to more efficient prevention and management of this headache disorder. The aim of the study was to investigate the relation of the three most studied <i>VDR</i> variants, i.e., <i>FokI</i> (rs2228570), <i>TaqI</i> (rs731236) and <i>BsmI</i> (rs1544410), with migraine susceptibility and distinct clinical phenotypes in a Southeastern European case-control population residing in Greece. DNA was extracted from 191 unrelated patients diagnosed with migraine and 265 headache-free controls and genotyped using real-time PCR (LightSNiP assays) followed by melting curve analysis. Genotype frequency distribution analysis of the <i>TaqI</i> and <i>BsmI</i> variants showed a statistically significant difference between migraine cases and controls. In addition, subgroup analyses revealed a significant association between all three studied <i>VDR</i> variants, particularly with a migraine without aura subtype. Therefore, the current study provides supporting evidence for a possible association of <i>VDR</i> variants with migraines, particularly migraine without aura susceptibility in Southeastern Europeans residing in Greece, further reinforcing the emerging role of vitamin D and its receptor in migraines.</p>","PeriodicalId":19130,"journal":{"name":"Neurology International","volume":"15 3","pages":"1117-1128"},"PeriodicalIF":3.0,"publicationDate":"2023-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536141/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41168026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Social Cognition Impairments in Association to Clinical, Cognitive, Mood, and Fatigue Features in Multiple Sclerosis: A Study Protocol.","authors":"Triantafyllos K Doskas,&nbsp;Foteini Christidi,&nbsp;Kanellos C Spiliopoulos,&nbsp;Dimitrios Tsiptsios,&nbsp;George D Vavougios,&nbsp;Anna Tsiakiri,&nbsp;Theofanis Vorvolakos,&nbsp;Christos Kokkotis,&nbsp;Ioannis Iliopoulos,&nbsp;Nikolaos Aggelousis,&nbsp;Konstantinos Vadikolias","doi":"10.3390/neurolint15030068","DOIUrl":"https://doi.org/10.3390/neurolint15030068","url":null,"abstract":"<p><p>Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system (CNS), characterized by the diffuse grey and white matter damage. Cognitive impairment (CI) is a frequent clinical feature in patients with MS (PwMS) that can be prevalent even in early disease stages, affecting the physical activity and active social participation of PwMS. Limited information is available regarding the influence of MS in social cognition (SC), which may occur independently from the overall neurocognitive dysfunction. In addition, the available information regarding the factors that influence SC in PwMS is limited, e.g., factors such as a patient's physical disability, different cognitive phenotypes, mood status, fatigue. Considering that SC is an important domain of CI in MS and may contribute to subjects' social participation and quality of life, we herein conceptualize and present the methodological design of a cross-sectional study in 100 PwMS of different disease subtypes. The study aims (a) to characterize SC impairment in PwMS in the Greek population and (b) to unveil the relationship between clinical symptoms, phenotypes of CI, mood status and fatigue in PwMS and the potential underlying impairment on tasks of SC.</p>","PeriodicalId":19130,"journal":{"name":"Neurology International","volume":"15 3","pages":"1106-1116"},"PeriodicalIF":3.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536405/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41144889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Migraine: Advances in the Pathogenesis and Treatment.","authors":"Horia Pleș,&nbsp;Ioan-Alexandru Florian,&nbsp;Teodora-Larisa Timis,&nbsp;Razvan-Adrian Covache-Busuioc,&nbsp;Luca-Andrei Glavan,&nbsp;David-Ioan Dumitrascu,&nbsp;Andrei Adrian Popa,&nbsp;Andrei Bordeianu,&nbsp;Alexandru Vlad Ciurea","doi":"10.3390/neurolint15030067","DOIUrl":"https://doi.org/10.3390/neurolint15030067","url":null,"abstract":"<p><p>This article presents a comprehensive review on migraine, a prevalent neurological disorder characterized by chronic headaches, by focusing on their pathogenesis and treatment advances. By examining molecular markers and leveraging imaging techniques, the research identifies key mechanisms and triggers in migraine pathology, thereby improving our understanding of its pathophysiology. Special emphasis is given to the role of calcitonin gene-related peptide (CGRP) in migraine development. CGRP not only contributes to symptoms but also represents a promising therapeutic target, with inhibitors showing effectiveness in migraine management. The article further explores traditional medical treatments, scrutinizing the mechanisms, benefits, and limitations of commonly prescribed medications. This provides a segue into an analysis of emerging therapeutic strategies and their potential to enhance migraine management. Finally, the paper delves into neuromodulation as an innovative treatment modality. Clinical studies indicating its effectiveness in migraine management are reviewed, and the advantages and limitations of this technique are discussed. In summary, the article aims to enhance the understanding of migraine pathogenesis and present novel therapeutic possibilities that could revolutionize patient care.</p>","PeriodicalId":19130,"journal":{"name":"Neurology International","volume":"15 3","pages":"1052-1105"},"PeriodicalIF":3.0,"publicationDate":"2023-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535528/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41105281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum GDF-15 Levels in Patients with Parkinson's Disease, Progressive Supranuclear Palsy, and Multiple System Atrophy.","authors":"Noriyuki Miyaue,&nbsp;Hayato Yabe,&nbsp;Masahiro Nagai","doi":"10.3390/neurolint15030066","DOIUrl":"10.3390/neurolint15030066","url":null,"abstract":"<p><p>Serum growth differentiation factor 15 (GDF-15) levels are elevated in patients with Parkinson's disease (PD) and may help differentiate these patients from healthy individuals. We aimed to clarify whether serum GDF-15 levels can help differentiate PD from atypical parkinsonian syndromes and determine the association between serum GDF-15 levels and clinical parameters. We prospectively enrolled 46, 15, and 12 patients with PD, progressive supranuclear palsy (PSP), and multiple system atrophy (MSA), respectively. The serum GDF-15 level in patients with PD (1394.67 ± 558.46 pg/mL) did not differ significantly from that in patients with PSP (1491.27 ± 620.78 pg/mL; <i>p</i> = 0.573) but was significantly higher than that in patients with MSA (978.42 ± 334.66 pg/mL; <i>p</i> = 0.017). Serum GDF-15 levels were positively correlated with age in patients with PD (<i>r</i> = 0.458; <i>p</i> = 0.001); PSP (<i>r</i> = 0.565; <i>p</i> = 0.028); and MSA (<i>r</i> = 0.708; <i>p</i> = 0.010). After accounting for age differences, serum GDF-15 levels did not differ significantly between patients with PD and MSA (<i>p</i> = 0.114). Thus, age has a strong influence on serum GDF-15 levels, which may not differ significantly between patients with PD and atypical parkinsonian syndromes such as PSP and MSA.</p>","PeriodicalId":19130,"journal":{"name":"Neurology International","volume":"15 3","pages":"1044-1051"},"PeriodicalIF":3.0,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535128/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41109560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atrial Fibrillation and Reperfusion Therapy in Acute Ischaemic Stroke Patients: Prevalence and Outcomes-A Comprehensive Systematic Review and Meta-Analysis.","authors":"Jay Patel,&nbsp;Sonu M M Bhaskar","doi":"10.3390/neurolint15030065","DOIUrl":"https://doi.org/10.3390/neurolint15030065","url":null,"abstract":"<p><p>Atrial fibrillation (AF) significantly contributes to acute ischaemic stroke (AIS), yet its precise influence on clinical outcomes post-intravenous thrombolysis (IVT) and post-endovascular thrombectomy (EVT) has remained elusive. Furthermore, the overall prevalence of AF in AIS patients undergoing reperfusion therapy has not been clearly determined. Employing random-effects meta-analyses, this research aimed to estimate the pooled prevalence of AF among AIS patients undergoing reperfusion therapy, while also examining the association between AF and clinical outcomes such as functional outcomes, symptomatic intracerebral haemorrhage (sICH) and mortality. Studies comparing AF and non-AF patient groups undergoing reperfusion therapy were identified and included following an extensive database search. Forty-nine studies (n = 66,887) were included. Among IVT patients, the prevalence of AF was 31% (Effect Size [ES] 0.31 [95%CI 0.28-0.35], <i>p</i> < 0.01), while in EVT patients, it reached 42% (ES 0.42 [95%CI 0.38-0.46], <i>p</i> < 0.01), and in bridging therapy (BT) patients, it stood at 36% (ES 0.36 [95%CI 0.28-0.43], <i>p</i> < 0.01). AF was associated with significantly lower odds of favourable 90-day functional outcomes post IVT (Odds Ratio [OR] 0.512 [95%CI 0.376-0.696], <i>p</i> < 0.001), but not post EVT (OR 0.826 [95%CI 0.651-1.049], <i>p</i> = 0.117). Our comprehensive meta-analysis highlights the varying prevalence of AF among different reperfusion therapies and its differential impact on patient outcomes. The highest pooled prevalence of AF was observed in EVT patients, followed by BT and IVT patients. Interestingly, our analysis revealed that AF was significantly associated with poorer clinical outcomes following IVT. Such an association was not observed following EVT.</p>","PeriodicalId":19130,"journal":{"name":"Neurology International","volume":"15 3","pages":"1014-1043"},"PeriodicalIF":3.0,"publicationDate":"2023-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537209/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41136488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Leukoaraiosis as a Promising Biomarker of Stroke Recurrence among Stroke Survivors: A Systematic Review.","authors":"Theofanis Dimaras,&nbsp;Ermis Merkouris,&nbsp;Dimitrios Tsiptsios,&nbsp;Foteini Christidi,&nbsp;Anastasia Sousanidou,&nbsp;Ilias Orgianelis,&nbsp;Efthymia Polatidou,&nbsp;Iordanis Kamenidis,&nbsp;Stella Karatzetzou,&nbsp;Aimilios Gkantzios,&nbsp;Christos Ntatsis,&nbsp;Christos Kokkotis,&nbsp;Sofia Retsidou,&nbsp;Maria Aristidou,&nbsp;Maria Karageorgopoulou,&nbsp;Evlampia A Psatha,&nbsp;Nikolaos Aggelousis,&nbsp;Konstantinos Vadikolias","doi":"10.3390/neurolint15030064","DOIUrl":"https://doi.org/10.3390/neurolint15030064","url":null,"abstract":"<p><p>Stroke is the leading cause of functional disability worldwide, with increasing prevalence in adults. Given the considerable negative impact on patients' quality of life and the financial burden on their families and society, it is essential to provide stroke survivors with a timely and reliable prognosis of stroke recurrence. Leukoaraiosis (LA) is a common neuroimaging feature of cerebral small-vessel disease. By researching the literature of two different databases (MEDLINE and Scopus), the present study aims to review all relevant studies from the last decade, dealing with the clinical utility of pre-existing LA as a prognostic factor for stroke recurrence in stroke survivors. Nineteen full-text articles published in English were identified and included in the present review, with data collected from a total of 34,546 stroke patients. A higher rate of extended LA was strongly associated with stroke recurrence in all stroke subtypes, even after adjustment for clinical risk factors. In particular, patients with ischemic stroke or transient ischemic attack with advanced LA had a significantly higher risk of future ischemic stroke, whereas patients with previous intracerebral hemorrhage and severe LA had a more than 2.5-fold increased risk of recurrent ischemic stroke and a more than 30-fold increased risk of hemorrhagic stroke. Finally, in patients receiving anticoagulant treatment for AF, the presence of LA was associated with an increased risk of recurrent ischemic stroke and intracranial hemorrhage. Because of this valuable predictive information, evaluating LA could significantly expand our knowledge of stroke patients and thereby improve overall stroke care.</p>","PeriodicalId":19130,"journal":{"name":"Neurology International","volume":"15 3","pages":"994-1013"},"PeriodicalIF":3.0,"publicationDate":"2023-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443317/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10058795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FTD/ALS Type 7-Associated Thr104Asn Mutation of CHMP2B Blunts Neuronal Process Elongation, and Is Recovered by Knockdown of Arf4, the Golgi Stress Regulator.","authors":"Remina Shirai,&nbsp;Mizuka Cho,&nbsp;Mikinori Isogai,&nbsp;Shoya Fukatsu,&nbsp;Miyu Okabe,&nbsp;Maho Okawa,&nbsp;Yuki Miyamoto,&nbsp;Tomohiro Torii,&nbsp;Junji Yamauchi","doi":"10.3390/neurolint15030063","DOIUrl":"https://doi.org/10.3390/neurolint15030063","url":null,"abstract":"<p><p>Frontotemporal dementia and/or amyotrophic lateral sclerosis type 7 (FTD/ALS7) is an autosomal dominant neurodegenerative disorder characterized by the onset of FTD and/or ALS, mainly in adulthood. Patients with some types of mutations, including the Thr104Asn (T104N) mutation of charged multivesicular body protein 2B (CHMP2B), have predominantly ALS phenotypes, whereas patients with other mutations have predominantly FTD phenotypes. A few mutations result in patients having both phenotypes approximately equally; however, the reason why phenotypes differ depending on the position of the mutation is unknown. CHMP2B comprises one part of the endosomal sorting complexes required for transport (ESCRT), specifically ESCRT-III, in the cytoplasm. We describe here, for the first time, that CHMP2B with the T104N mutation inhibits neuronal process elongation in the N1E-115 cell line, a model line undergoing neuronal differentiation. This inhibitory phenotype was accompanied by changes in marker protein expression. Of note, CHMP2B with the T104N mutation, but not the wild-type form, was preferentially accumulated in the Golgi body. Of the four major Golgi stress signaling pathways currently known, the pathway through Arf4, the small GTPase, was specifically upregulated in cells expressing CHMP2B with the T104N mutation. Conversely, knockdown of Arf4 with the cognate small interfering (si)RNA recovered the neuronal process elongation inhibited by the T104N mutation. These results suggest that the T104N mutation of CHMP2B inhibits morphological differentiation by triggering Golgi stress signaling, revealing a possible therapeutic molecular target for recovering potential molecular and cellular phenotypes underlying FTD/ALS7.</p>","PeriodicalId":19130,"journal":{"name":"Neurology International","volume":"15 3","pages":"980-993"},"PeriodicalIF":3.0,"publicationDate":"2023-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443297/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10114341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In Search of a Function for the N6-Methyladenosine in Epitranscriptome, Autophagy and Neurodegenerative Diseases.","authors":"Naoko Suga,&nbsp;Yuka Ikeda,&nbsp;Sayuri Yoshikawa,&nbsp;Kurumi Taniguchi,&nbsp;Haruka Sawamura,&nbsp;Satoru Matsuda","doi":"10.3390/neurolint15030062","DOIUrl":"https://doi.org/10.3390/neurolint15030062","url":null,"abstract":"<p><p>Changes in epitranscriptome with N6-methyladenine (m6A) modification could be involved in the development of multiple diseases, which might be a prevalent modification of messenger RNAs (mRNAs) in eukaryotes. The m6A modification might be performed through the action of methyltransferases, demethylases, and methylation-binding proteins. Importantly, the m6A methylation may be associated with various neurological disorders including Alzheimer's disease (AD), Parkinson's disease (PD), depression, aging-related diseases, and/or aging itself. In addition, the m6A methylation might functionally regulate the eukaryotic transcriptome by influencing the splicing, export, subcellular localization, translation, stability, and decay of mRNAs. Neurodegenerative diseases may possess a wide variety of phenotypes, depending on the neurons that degenerate on occasion. Interestingly, an increasing amount of evidence has indicated that m6A modification could modulate the expression of autophagy-related genes and promote autophagy in neuronal cells. Oxidative stresses such as reactive oxygen species (ROS) could stimulate the m6A RNA methylation, which may also be related to the regulation of autophagy and/or the development of neurodegenerative diseases. Both m6A modification and autophagy could also play critical roles in regulating the health condition of neurons. Therefore, a comprehensive understanding of the m6A and autophagy relationship in human diseases may benefit in developing therapeutic strategies in the future. This paper reviews advances in the understanding of the regulatory mechanisms of m6A modification in the occurrence and development of neurodegenerative diseases and/or aging, discussing the possible therapeutic procedures related to mechanisms of m6A RNA methylation and autophagy.</p>","PeriodicalId":19130,"journal":{"name":"Neurology International","volume":"15 3","pages":"967-979"},"PeriodicalIF":3.0,"publicationDate":"2023-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443253/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10413849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modified TPP-MoS₂ QD Blend as a Bio-Functional Model for Normalizing Microglial Dysfunction in Alzheimer's Disease.","authors":"Ohoud A Alomari,&nbsp;Safaa Qusti,&nbsp;Maha Balgoon,&nbsp;Fadwa Aljoud,&nbsp;Khalid A Alamry,&nbsp;Mahmoud A Hussein","doi":"10.3390/neurolint15030061","DOIUrl":"https://doi.org/10.3390/neurolint15030061","url":null,"abstract":"<p><p>Alzheimer's disease (AD) is the most prevalent neurodegenerative disease of old age. Accumulation of β-amyloid peptide (Aβ) and mitochondrial dysfunction results in chronic microglial activation, which enhances neuroinflammation and promotes neurodegeneration. Microglia are resident macrophages of the brain and spinal cord which play an important role in maintaining brain homeostasis through a variety of phenotypes, including the pro-inflammatory phenotype and anti-inflammatory phenotypes. However, persistently activated microglial cells generate reactive species and neurotoxic mediators. Therefore, inhibitors of microglial activation are seen to have promise in AD control. The modified TPP/MoS₂ QD blend is a mitochondrion-targeted nanomaterial that exhibits cytoprotective activities and antioxidant properties through scavenging free radicals. In the present study, the cell viability and cytotoxicity of the DSPE-PEG-TPP/MoS₂ QD blend on microglial cells stimulated by Aβ were investigated. The levels of reactive oxygen species (ROS) and mitochondrial membrane potential (MMP) were also assessed. In addition, pro-inflammatory and anti-inflammatory cytokines, such as tumor necrosis factor α (TNF-α), interleukin-6 (IL-6), interleukin-1β (IL-1β), transforming growth factor beta (TGF-β), inducible nitric oxide synthase (iNOS) and arginase-1 (Arg-I) were measured in the presence or absence of the DSPE-PEG-TPP/MoS₂ QD blend on an immortalized microglia cells activated by accumulation of Aβ. We found that the DSPE-PEG-TPP/MoS₂ QD blend was biocompatible and nontoxic at specific concentrations. Furthermore, the modified TPP/MoS₂ QD blend significantly reduced the release of free radicals and improved the mitochondrial function through the upregulation of MMP in a dose-dependent manner on microglial cells treated with Aβ. In addition, pre-treatment of microglia with the DSPE-PEG-TPP/MoS₂ QD blend at concentrations of 25 and 50 μg/mL prior to Aβ stimulation significantly inhibited the release and expression of pro-inflammatory cytokines, such as IL-1β, IL-6, TNF-α, and iNOS. Nevertheless, the anti-inflammatory cytokines TGF-β and Arg-I were activated. These findings suggest that the modified TPP/MoS₂ QD blend reduced oxidative stress, inflammation and improved the mitochondrial function in the immortalized microglial cells (IMG) activated by Aβ. Overall, our research shows that the DSPE-PEG-TPP/MoS₂ QD blend has therapeutic promise for managing AD and can impact microglia polarization.</p>","PeriodicalId":19130,"journal":{"name":"Neurology International","volume":"15 3","pages":"954-966"},"PeriodicalIF":3.0,"publicationDate":"2023-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443245/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10432880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating the Predictive Value of Thyroid Hormone Levels for Stroke Prognosis.","authors":"Aimilios Gkantzios,&nbsp;Vaia Karapepera,&nbsp;Dimitrios Tsiptsios,&nbsp;Eirini Liaptsi,&nbsp;Foteini Christidi,&nbsp;Elena Gkartzonika,&nbsp;Stella Karatzetzou,&nbsp;Christos Kokkotis,&nbsp;Mihail Kyrtsopoulos,&nbsp;Anna Tsiakiri,&nbsp;Paschalina Bebeletsi,&nbsp;Sofia Chaidemenou,&nbsp;Christos Koutsokostas,&nbsp;Konstantinos Tsamakis,&nbsp;Maria Baltzi,&nbsp;Dimitrios Mpalampanos,&nbsp;Nikolaos Aggelousis,&nbsp;Konstantinos Vadikolias","doi":"10.3390/neurolint15030060","DOIUrl":"https://doi.org/10.3390/neurolint15030060","url":null,"abstract":"<p><p>Given the expansion of life expectancy, the aging of the population, and the anticipated rise in the number of stroke survivors in Europe with severe neurological consequences in the coming decades, stroke is becoming the most prevalent cause of functional disability. Therefore, the prognosis for a stroke must be timely and precise. Two databases (MEDLINE and Scopus) were searched to identify all relevant studies published between 1 January 2005 and 31 December 2022 that investigated the relationship between thyroid hormone levels and acute stroke severity, mortality, and post-hospital prognosis. Only full-text English-language articles were included. This review includes Thirty articles that were traced and incorporated into the present review. Emerging data regarding the potential predictive value of thyroid hormone levels suggests there may be a correlation between low T3 syndrome, subclinical hypothyroidism, and poor stroke outcome, especially in certain age groups. These findings may prove useful for rehabilitation and therapy planning in clinical practice. Serum thyroid hormone concentration measurement is a non-invasive, relatively harmless, and secure screening test that may be useful for this purpose.</p>","PeriodicalId":19130,"journal":{"name":"Neurology International","volume":"15 3","pages":"926-953"},"PeriodicalIF":3.0,"publicationDate":"2023-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443262/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10432879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}